Masimo SET®: Clinically Proven

 

The accuracy and reliability of Masimo SET® pulse oximetry have been studied in challenging conditions

Over 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies.1

  • On a post-surgical unit it was found that:
    • Rescue calls and ICU transfers were reduced by 65% and 48%, respectively, after the implementation of continuous surveillance monitoring with Masimo SET®.2
    • Over five years, clinicians achieved their goal of zero preventable deaths or brain damage due to opioids.3
    • Over ten years, clinicians maintained a 50% reduction in unplanned transfers and a 60% reduction in rescue events, despite increases in patient acuity and occupancy.4
  • In a PACU, Masimo SET® had a greater than 50% reduction in false alarms compared to other pulse oximetry technology.5
  • In a study of 122,738 infants, critical congenital heart disease (CCHD) screening sensitivity increased from 77% to 93% with the combined use of Masimo SET® and clinical assessment.6
  • In a study of 39,821 infants, CCHD screening sensitivity increased from 63% with physical exam alone to 83% with physical exam and Masimo SET® pulse oximetry.7
  • In two NICU settings, Masimo SET®, coupled with changes in clinical practice, showed significantly reduced rates of severe retinopathy of prematurity (ROP) and decreased the need for laser treatment.8,9
  • Researchers showed time to reliable oxygen saturation readings during neonatal resuscitation was approximately 50 seconds faster using Masimo SET® than using other pulse oximetry technologies.10
“I saw and was conquered. I was not able to defeat the Masimo SET® pulse oximeter using all the motion and low pulse tricks I know. This technology is most impressive and should be available in all oximeters.”

John Severinghaus, M.D.
Professor of Anesthesiology, Emeritus University of California, San Francisco

The Performance of Masimo SET®

 

CCHD Screening

Improved Critical Congenital Heart Disease Screening
Sensitivity vs. Clinical Assessment Alone

Improved Critical Congenital Heart Disease Screening Sensitivity vs. Clinical Assessment Alone
  • When combined with clinical assessment, Masimo SET® improved critical congenital heart disease (CCHD) screening sensitivity to 93%6

Retinopathy of Prematurity

Severe Retinopathy of Prematurity Rate

Severe Retinopathy of Prematurity Rate
  • Masimo SET®, coupled with changes in clinical practice, led to a significant reduction in rates of severe retinopathy of prematurity (ROP)8

Performance During Motion and Low Perfusion

Masimo - Performance through Low Performance Chart
  • Masimo SET® had 3% missed true alarms and 5% false alarms versus 43% and 28%, respectively, using competitor technology11*

*Results shown are calculated by combining sensitivity and specificity outcomes of machine-generated and volunteer-generated motion.

Learn More About Masimo SET®

 

References:

  1. 1.

    Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at  http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.

  2. 2.

    Taenzer AH et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.

  3. 3.

    Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.

  4. 4.

    McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.

  5. 5.

    Malviya S et al. False Alarms and Sensitivity of Conventional Pulse Oximetry Versus the Masimo SET® Technology in the Pediatric Postanesthesia Care Unit. Anesth Analg 2000; 90(6):1336-1340.

  6. 6.

    Zhao et al. Pulse oximetry with clinical assessment to screen for congenital heart disease in neonates in China: a prospective study. Lancet 2014 Aug 30;384(9945):747-54.

  7. 7.

    de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ 2009;338:a3037.

  8. 8.

    Castillo et al. Prevention of retinopathy of prematurity in preterm infants through changes in clinical practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.

  9. 9.

    Sola et al. Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants? Pediatrics 2003;111(2):339-345.

  10. 10.

    Baquero H et al. Avoiding Hyperoxemia during Neonatal Resuscitation: Time to Response of Different SpO2 Monitors. Acta Paediatr. 2011 Apr;100(4):515-8.

  11. 11.

    Shah et al. Performance of Three New-Generation Pulse Oximeters during Motion and Low Perfusion in Volunteers. J Clin Anesth. 2012;24(5):385-91.

RESOURCES

 

Masimo SET Studies

Follow the link for available Masimo SET studies.

Masimo - Product Information Masimo SET
Masimo SET

Product Information

Masimo - Production Information Masimo SET Reduced Cost of Care
Masimo SET: Reduced Cost of Care

Product Information

Masimo - A New Standard of Care with Masimo SET Pulse Oximetry
A New Standard of Care with Masimo SET® Pulse Oximetry

Video

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, and precautions.

PLCO-002697/PLM-10297D-0319